TY - JOUR
T1 - Global overview of the transnational alliance for regenerative therapies in cardiovascular syndromes (TACTICS) Recommendations
T2 - A comprehensive series of challenges and priorities of cardiovascular regenerative medicine
AU - Fernández-Avilés, Francisco
AU - Sanz-Ruiz, Ricardo
AU - Climent, Andreu M.
AU - Badimon, Lina
AU - Bolli, Roberto
AU - Charron, Dominique
AU - Fuster, Valentin
AU - Janssens, Stefan
AU - Kastrup, Jens
AU - Kim, Hyo Soo
AU - Löscher, Thomas F.
AU - Martin, John F.
AU - Menasché, Philippe
AU - Pinto, Fausto J.
AU - Simari, Robert D.
AU - Stone, Gregg W.
AU - Terzic, Andre
AU - Willerson, James T.
AU - Wu, Joseph C.
N1 - Funding Information:
This work was supported by the Spanish Ministry of Economy through the Instituto de Salud Carlos IIIFEDER (Fondo Europeo de Desarrollo Regional; PLE2009-0152, IJCI-2014-22178, PI13-01882, SAF2016-76819-R, CPII15/00017), the Red de Investigación Cardiovacular (RIC. RD12.0042.0001) and the Red of Terapia Celular (TERCEL. RD12.0019.0021, RD16/00110018 and CB16/ 11/0041); FEDER ‘Una Manera de Hacer Europa’; and ‘CERCA Programme/Generalitat de Catalunya’ Spain (in part); BAMI (7th FP); SCIENCE (Horizon 2020), Pegasus, Circulate (STRATEGMED by Polish National Centre for Research and Development), statutory funds Medical University of Silesia; NIH and the Mayo Foundation. Netherlands CardioVascular Research Initiative (CVON): The Dutch Heart Foundation, Dutch Federation of University Medical Centers, the Netherlands Organization for Health Research and Development and the Royal Netherlands Academy of Science. Academy of Finland. National Institutes of Health (R01HL084275, R01HL107110, UM1HL113460, and R01HL110737); Starr and Soffer Family Foundations; HLA&MEDECINE.NIH (R01HL067245, R37HL091102, R01HL 105759, R01HL113647, R01HL117163, P01HL085577, R01HL 122525, P01 HL-78825, and 1 UM1 HL-113530 (CCTRN)) (in part). A. Terzic reports research grants, administered by Mayo Clinic, from Marriott Foundation, Michael S. and Mary Sue Shannon Family, Russ and Kathy VanCleve Foundation, Leducq Foundation, Florida Heart Research Institute, Celyad, and National Institutes of Health. Ministerio de Educación y Ciencia (SAF2014-59892), Fundación La MARATO de TV3 (201502, 201516), Red de Terapia Celular - TerCel (RD16/0011/0006) and CIBER Cardiovascular (CB16/11/00403) as part of the Plan Nacional de I+D+I.
Funding Information:
National Institutes of Health (R01HL084275, R01HL107110, UM1HL113460, and R01HL110737); Starr and Soffer Family Foundations; HLA&MEDECINE.NIH (R01HL067245, R37HL091102, R01HL 105759, R01HL113647, R01HL117163, P01HL085577, R01HL 122525, P01 HL-78825, and 1 UM1 HL-113530
Publisher Copyright:
© 2018 American Heart Association, Inc.
PY - 2018/1
Y1 - 2018/1
N2 - Cardiovascular regenerative medicine (CRM) has been defined as an innovative research field that includes all diagnostic and therapeutic strategies aimed at restoring cardiovascular health by enhancing the innate regenerative response of cardiac and vascular tissues.1 The TACTICS (Transnational Alliance for Regenerative Therapies in Cardiovascular Syndromes) was created in 2015 with the vision of advancing CRM through synergy of basic discoveries and translational clinical efforts in the fight against cardiovascular failure and has grown to include >100 research groups worldwide.2 This unprecedented initiative stated as specific missions the redefinition of CRM and advanced therapy regenerative products, the establishment of discovery and development priorities for the next decade, and the attainment and dissemination of a consensual strategy to reinforce the field increasing its credibility. The first milestone of TACTICS has been achieved with the publication of a Global Consensus Document.1 However, given the amplitude and relevance of its different chapters, a more detailed description of all of them has been deemed necessary, following the same scheme of the Global Consensus Document and, therefore, discussing the main topics and priorities of the CRM field. This is the final aim of this Cardiovascular Regenerative and Reparative Medicine Circulation Research review series. In this first chapter, the following ones are presented and summarized in the form of and index of consecutive articles, which will cover biological fundamentals, preclinical models, and all clinical research-related issues. These articles will be regularly and subsequently published in this journal, on behalf of the TACTICS Consortium (Figure).
AB - Cardiovascular regenerative medicine (CRM) has been defined as an innovative research field that includes all diagnostic and therapeutic strategies aimed at restoring cardiovascular health by enhancing the innate regenerative response of cardiac and vascular tissues.1 The TACTICS (Transnational Alliance for Regenerative Therapies in Cardiovascular Syndromes) was created in 2015 with the vision of advancing CRM through synergy of basic discoveries and translational clinical efforts in the fight against cardiovascular failure and has grown to include >100 research groups worldwide.2 This unprecedented initiative stated as specific missions the redefinition of CRM and advanced therapy regenerative products, the establishment of discovery and development priorities for the next decade, and the attainment and dissemination of a consensual strategy to reinforce the field increasing its credibility. The first milestone of TACTICS has been achieved with the publication of a Global Consensus Document.1 However, given the amplitude and relevance of its different chapters, a more detailed description of all of them has been deemed necessary, following the same scheme of the Global Consensus Document and, therefore, discussing the main topics and priorities of the CRM field. This is the final aim of this Cardiovascular Regenerative and Reparative Medicine Circulation Research review series. In this first chapter, the following ones are presented and summarized in the form of and index of consecutive articles, which will cover biological fundamentals, preclinical models, and all clinical research-related issues. These articles will be regularly and subsequently published in this journal, on behalf of the TACTICS Consortium (Figure).
UR - http://www.scopus.com/inward/record.url?scp=85047019873&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85047019873&partnerID=8YFLogxK
U2 - 10.1161/CIRCRESAHA.117.312099
DO - 10.1161/CIRCRESAHA.117.312099
M3 - Review article
C2 - 29348246
AN - SCOPUS:85047019873
SN - 0009-7330
VL - 122
SP - 199
EP - 201
JO - Circulation research
JF - Circulation research
IS - 2
ER -